 |
|
|
|
 |
|
|
 Contact |  Print version |  PDF version |  Send article |  RSS-Feed
First human study with vasopharm's trauma compound VAS20311 Jan 2007 -
vasopharm GmbH announced that the company has received a positive ethics vote from the Landesärztekammer Baden-Württemberg, Stuttgart, Germany and the necessary approval from the Federal Institute for Drugs and Medical Devices, Germany (BfArM) for the first study in humans of VAS203.
The goal of the upcoming phase I study which will start in January 2007 is to demonstrate safety, tolerability and pharmacokinetics of ascending single intravenous administrations of VAS203 in healthy volunteers. Provided that the enrolment of the volunteers proceeds as intended the results of the study are expected in June 2007. The single dose administration study will then be followed by a multiple dose study which is currently planned for July 2007.
Additional information
vasopharm BIOTECH GmbH
Würzburg, Germany
Company
News
|
|
|
|
|
|
Top